Alleviating Recombinant Tissue Plasminogen Activator‐induced Hemorrhagic Transformation in Ischemic Stroke via Targeted Delivery of a Ferroptosis Inhibitor
Open Access
- 22 April 2024
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 11 (24) , e2309517
Abstract
Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) is the primary treatment for ischemic stroke. However, rtPA treatment can substantially increase blood‐brain barrier (BBB) permeability and susceptibility to hemorrhagic transformation. Herein, the mechanism underlying the side effects of rtPA treatment is investigated and demonstrated that ferroptosis plays an important role. The ferroptosis inhibitor, liproxstatin‐1 (Lip) is proposed to alleviate the side effects. A well‐designed macrocyclic carrier, glucose‐modified azocalix[4]arene (GluAC4A), is prepared to deliver Lip to the ischemic site. GluAC4A bound tightly to Lip and markedly improved its solubility. Glucose, modified at the upper rim of GluAC4A, imparts BBB targeting to the drug delivery system owing to the presence of glucose transporter 1 on the BBB surface. The responsiveness of GluAC4A to hypoxia due to the presence of azo groups enabled the targeted release of Lip at the ischemic site. GluAC4A successfully improved drug accumulation in the brain, and Lip@GluAC4A significantly reduced ferroptosis, BBB leakage, and neurological deficits induced by rtPA in vivo. These findings deepen the understanding of the side effects of rtPA treatment and provide a novel strategy for their effective mitigation, which is of great significance for the treatment and prognosis of patients with ischemic stroke.Keywords
Funding Information
- National Natural Science Foundation of China (82071316, 82371320, U20A20259)
- National Key Clinical Specialty Discipline Construction Program of China (TJYXZDXK‐052B)
This publication has 53 references indexed in Scilit:
- An Antitumor Dual‐Responsive Host‐Guest Supramolecular Polymer Based on Hypoxia‐Cleavable Azocalix[4]areneAngewandte Chemie International Edition, 2022
- Suprasomes Based on Host–Guest Molecular Recognition: An Excellent Alternative to Liposomes in Cancer TheranosticsAngewandte Chemie International Edition, 2022
- Metabolic Rewiring of Kynurenine Pathway during Hepatic Ischemia–Reperfusion Injury Exacerbates Liver Damage by Impairing NAD HomeostasisAdvanced Science, 2022
- Promoting Tumor Accumulation of Anticancer Drugs by Hierarchical Carrying of Exogenous and Endogenous VehiclesSmall Structures, 2022
- Drug in Drug: A Host–Guest Formulation of Azocalixarene with Hydroxychloroquine for Synergistic Anti‐InflammationAdvanced Materials, 2022
- Macrocyclic‐Amphiphile‐Based Self‐Assembled Nanoparticles for Ratiometric Delivery of Therapeutic Combinations to TumorsAdvanced Materials, 2021
- Inhibition of ferroptosis‐like cell death attenuates neuropathic pain reactions induced by peripheral nerve injury in ratsEuropean journal of pain, 2021
- A General Hypoxia‐Responsive Molecular Container for Tumor‐Targeted TherapyAdvanced Materials, 2020
- Editorial: Drug Delivery: Too Much Complexity, Not Enough Reproducibility?Angewandte Chemie International Edition, 2017
- Calixarenes, Macrocycles with (Almost) Unlimited PossibilitiesAngewandte Chemie International Edition, 1995